Clinical

NIH Trial – HERV-E TCR Transduced Autologous T Cells in People with Metastatic Clear Cell Kidney Cancer.    Good News!  Since I last shared news of this exciting clear cell kidney cancer trial it has continued to actively recruit.  If you are interested there are still spots available.  Eligibility criteria include: Being at least 18, having clear cell RCC, measurable disease progression in the last six months; and being positive for HLA-A 11:01. HLA-A 11:01 is only present in a subset of clear cell RCC patients.  The NIH, at no charge, can arrange testing for you if you are interested in finding out if you are positive for HLA-A 11:01.    Additionally, there are some eligibility requirements related to prior treatments. The trial involves...